The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346. Hengrui Pharma will ...

With the CSF-1R inhibitor space heating up, Merck KGaA ... license to the drug. The German pharma originally paid $70 million for the greater China commercialization rights back in 2023, while ...

including 64 million people in the U.S. Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide ...